Growth in this market is driven mainly by the increasing incidence of chronic diseases, government investments for cell-based research, the growing focus on personalized medicine, increasing focus on R&D for cell-based therapies, and growing GMP certifications for cell therapy production facilities.
Cell-based approaches, primarily using mesenchymal stromal cells (MSCs), offers a promising approach toward mitigating the adverse effects of the COVID-19 infection. This therapy has been shown to reduce the expression of pro-inflammatory cytokines as well as repair damaged tissues in COVID-19 patients.
According to the WHO ICTRP and the NIH ClinicalTrials.gov databases, 27 clinical investigations of MSC-based cell therapy approaches have begun in China since the onset of the COVID-19 outbreak, as well as a growing number of academic and industry trials elsewhere. Regenerative medicine & stem cell research is one of the major applications of cell expansion. This is a major indicator of market growth as stem cell-based therapies are showing significant potential in the COVID-19 study.
Cell expansion is used in the R&D of drugs for the treatment of diseases. It is used in the production of vaccines, drugs, therapeutics, and antibiotics. The rising incidence of diseases such as diabetes and cancer has created a need for extensive research to develop new treatment options.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194978883
Research in cell biology necessitates the use of animals and humans, as animal and human cells are used in gene therapy studies that involve the recombination of genes and stem cell research therapies. These cells are also used for in vivo toxicity and pharmacokinetic testing of drugs, which may harm animals and humans. In addition, stem cell research studies use human embryos for clinical applications that often lead to the destruction of human embryos.
To monitor these activities, strict regulations have been formulated by ethical authorities in various countries across the globe. Authorities such as the Human Tissue Authority (HTA), Human Fertilization and Embryology Authority (HFEA), Medicines and Healthcare products Regulatory Agency (MHRA), and Central Ethics Committee for Stem Cell Research (ZES), among others, have implemented stringent regulations for cell biology research.
These ethical concerns and restrictions on the use of cells for research are limiting cell biology research to a great extent in various countries across the globe. This, in turn, is expected to restrict the growth of the cell expansion market.
Some of the leading players in the cell expansion market include Thermo Fisher Scientific, Inc. (US), Danaher (US), Becton, Dickinson and Company (US), Lonza (Switzerland), Corning, Inc. (US), Merck KGaA (Germany), Sartorius Stedim Biotech (France), Getinge AB (Sweden) Terumo Corporation (Japan), and Miltenyi Biotec (Germany)